trending Market Intelligence /marketintelligence/en/news-insights/trending/nAky-fOhMhnC3Y-Se8QOvA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

MabVax stockholders approve reverse stock split

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


MabVax stockholders approve reverse stock split

MabVax Therapeutics Holdings Inc. stockholders approved the implementation of a reverse stock split of its issued and outstanding common shares at a special meeting held Oct. 6.

The company may initiate the stock split at any time prior to Sept. 28, 2018. The exact split ratio is still pending on the board's direction but will not be less than 1-for-2 and not more than 1-for-20.

The reverse stock split will allow MabVax to regain compliance with Nasdaq Capital Market's $1 minimum bid price listing requirement. The company has 180 calendar days, or until March 5, 2018 to regain compliance with the listing standard.